Status:
COMPLETED
Effect of Gabapentin on GABA Concentration and Emotional Processing
Lead Sponsor:
National Institute of Mental Health (NIMH)
Conditions:
Healthy
Eligibility:
All Genders
18-60 years
Brief Summary
This study will use magnetic resonance spectroscopy (MRS) and the drug gabapentin to examine the role of the brain chemical gamma-amino-butyric acid (GABA) in regulating emotions in healthy people. Ga...
Detailed Description
Gamma-aminobutyric acid (GABA) is a major inhibitory neurotransmitter in the forebrain structures, and the GABAergic system has been found to have roles in attentional and learning processes, recognit...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Family history of mental illness (mood and anxiety disorders, schizophrenia and other psychotic disorders, substance abuse disorders) will be obtained in all 1st degree relatives using the Family Interview of Genetic Studies.
- Healthy Control Samples: 34 healthy subjects (ages 18-60) without a known personal or family history of psychiatric disorders in first-degree relatives will be selected.
- EXCLUSION CRITERIA:
- Pregnant females will be excluded due to the potential risk of magnetic field exposure during pregnancy.
- If any subject appears incapable of providing informed consent, they will be excluded from the study.
- Subjects must not have taken centrally active medication for at least 3 weeks prior to the study.
- Subjects will also be excluded if they have: a) medical or neurological illnesses likely to affect physiology or anatomy, i.e. hypertension, cardiovascular disorders, b) a history of drug (including benzodiazepines \[BZD\]) or alcohol abuse, c) smokers, d) serious suicidal ideation or behavior, e) lactose intolerance, f) caffeine dependency, g) history of allergic reaction to GBP, and h) general MRI exclusion criteria.
- Subjects must exhibit no or only moderate alcohol use.
- Subjects beyond age 60 are excluded because of slower elimination of GBP in older adults, and the age-related increase in brain structural abnormalities.
- In women, there are additional exclusion criteria: i) current pregnancy (as documented by pregnancy testing at screening or at days of the challenge studies), j) current breast feeding, k) lack of reliable contraception method.
Exclusion
Key Trial Info
Start Date :
October 14 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 3 2010
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00094510
Start Date
October 14 2004
End Date
September 3 2010
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892